HSP90 inhibition overcomes EGFR amplification‐induced resistance to third‐generation EGFR‐TKIs
Abstract Background Patients with non‐small cell lung cancer (NSCLC) harboring activating EGFR mutations are sensitive to epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) but inevitably develop resistance to the inhibitors mostly through acquisition of the secondary T790M muta...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-03-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.13839 |